Dianthus Therapeutics, Inc. - Common Stock (DNTH)

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement.

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Dianthus Therapeutics just reported results for the third quarter of 2023.

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the 

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.